Global Blood Therapeutics

Founded in 2011 by Andrej Sali, David Phillips, Jack Taunton, and Matthew Jacobson, Global Blood Therapeutics is a South San Francisco-based biopharmaceutical company developing targeted treatments for sickle cell disease. The organization commercializes its lead therapeutic product, Oxbryta, which received FDA approval in 2019 to treat the root cause of this severe hereditary blood disorder. Operating with approximately 389 employees, the enterprise traded publicly on the NASDAQ exchange and reached a market capitalization of $4.62 billion after securing $300 million in total funding. Under the leadership of Chief Executive Officer Ted Love, the business expanded its distribution across the United States, Europe, Latin America, and the Middle East to serve affected patients. This core mission to transform the disease into a well-managed condition ultimately culminated in a definitive acquisition agreement with Pfizer for $5.4 billion.